Stages of Perimenopause: How to Tell Which Stage You're In

Last updated: August 2026 · Educational information, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

The stages of perimenopause are best understood as two clinical menopausal-transition stages—early and late—plus two practical checkpoints: possible early changes before the calendar threshold and the 12-month window that confirms menopause. The checkable rules are a persistent 7-day difference between consecutive cycle lengths and one interval of 60 days or more without bleeding.

By The HRT Index Editorial Team · Educational research, not medical advice · Not reviewed by a clinician · Last verified: August 2026

Affiliate disclosure: Sponsored Midi and Sesame links appear later on this page. The HRT Index may earn a commission at no extra cost to you. Read the full disclosure.

This page is for you if you've noticed something change and want to know where you are on the map, how long the transition can run, and what information is worth bringing to a clinician.

This page is not for you if you already know your stage and want treatment options (start with Types of HRT), you're comparing providers (start with Best Online HRT Providers), or heavy or unpredictable bleeding is your main problem (start with Perimenopause Irregular Periods: Treatment Online).

Your practical checkpoint	The signal you may notice	What it means
1. Possible early changes	Periods may still look regular, while flow, duration, sleep, temperature regulation, mood, or other symptoms change	Something may be shifting, but the STRAW+10 transition criteria have not necessarily been met
2. Early menopausal transition	A difference of 7 days or more between consecutive cycle lengths that recurs within 10 cycles	Your natural cycle pattern resembles the clinical early-transition stage
3. Late menopausal transition	One interval of 60 days or more without bleeding	Your natural cycle pattern resembles the clinical late-transition stage
4. The 12-month confirmation window	Twelve consecutive months without a natural period, with no other cause	Menopause can be confirmed retrospectively; any later bleeding needs evaluation

Here's the part almost nobody tells you: your age does not assign a STRAW+10 stage, your symptoms do not assign one, and a single blood test usually cannot either. In cohorts of women over 40, a 60-day interval without bleeding predicted proximity to the final menstrual period better than a single early-follicular FSH result did.

And here's the open loop we're going to close. If your periods still look regular but you feel like something has changed, the confusion is real: the research staging standard starts at a cycle threshold, a 2025 clinical guideline says perimenopause should be considered when menstrual irregularity and/or vasomotor symptoms are present, and one university research center uses an explicitly non-consensus symptom checklist for an earlier phase. We'll show you exactly where those frameworks split—and what each one can and cannot tell you.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

One quick note before we go further. If you're soaking through a pad or tampon every hour for two to three hours, bleeding heavily enough to feel weak or lightheaded, having severe pain, or could be pregnant, stop treating this as a staging question and get medical help now.

What are the stages of perimenopause?

Clinically, there are two menopausal-transition stages: early and late. For real-life decision-making, this page uses four practical checkpoints—possible early changes, early transition, late transition, and the 12-month confirmation window. The final period itself is Stage 0 in STRAW+10, but it can only be identified in hindsight.

STRAW+10—the Stages of Reproductive Aging Workshop +10—maps reproductive aging around the final menstrual period. The transition years are Stage −2 and Stage −1. Stage 0 is the final menstrual period. Stage +1 is early postmenopause.

That is why the phrase “four stages of perimenopause” creates so much trouble. Four can be a useful teaching frame. It is not the number of official menopausal-transition stages.

The four practical checkpoints

Practical checkpoint	Official status	The rule or clue	What it supports	What it cannot prove	The useful next move
1. Possible early changes	Usually late reproductive stage in STRAW+10, not yet a clinical transition stage	Cycles may remain regular; flow, duration, or symptoms may change	Your baseline is changing and deserves tracking or evaluation	That perimenopause is the cause; that you meet a clinical stage	Track period starts, bleeding, and symptom impact; rule out other causes when needed
2. Early menopausal transition	STRAW+10 Stage −2	Persistent difference of 7 days or more between consecutive cycle lengths; persistence is operationalized as recurrence within 10 cycles	Your observable natural-cycle pattern resembles early transition	An exact hormone level, a diagnosis of every symptom, or a personal menopause date	Bring the dates and calculated differences to a clinician; discuss symptoms now if they are disrupting life
3. Late menopausal transition	STRAW+10 Stage −1	One interval of 60 days or more without bleeding	Your observable natural-cycle pattern resembles late transition and is generally closer to the final period	That the last period was definitely the final one; that pregnancy is impossible	Keep tracking; continue contraception when pregnancy is not wanted; evaluate unusual bleeding
4. The 12-month confirmation window	Stage 0 is the final period; the following year is early postmenopause in STRAW+10 and still inside WHO's broader perimenopause definition	Twelve consecutive months without natural menstruation, when not explained by pregnancy, surgery, medication, or another cause	Menopause can be confirmed retrospectively	That any later bleeding is “just another period”	Report any bleeding after the 12-month mark for prompt evaluation

The distinction is not wordplay. It keeps a practical map useful without turning it into a fake clinical system.

Where the official STRAW+10 labels sit

STRAW+10 point	Official name	What the calendar can show	What it means for this page
−3b / −3a	Late reproductive stages	Cycles may still be regular; subtle changes may occur	Possible early-change checkpoint, but not an official transition stage
−2	Early menopausal transition	Persistent 7-day-or-greater difference between consecutive cycle lengths	First clinical transition stage
−1	Late menopausal transition	At least one 60-day interval without bleeding	Second clinical transition stage
0	Final menstrual period	Not identifiable on the day it happens	Known only after the 12-month confirmation window
+1a	Early postmenopause	The first year after the final period	Postmenopause in STRAW+10; still within WHO's broader perimenopause window until the year is complete

The World Health Organization defines perimenopause as beginning when transition signs are first observed and ending one year after the final menstrual period. STRAW+10 uses a more exact research-stage map. Both can be true because they are answering different questions.

Age matters—but it does a different job

STRAW+10 was designed to apply regardless of age, ethnicity, body size, or lifestyle. That does not mean age is medically irrelevant.

Age changes what should be investigated:

Symptoms or cycle disruption under 40 should trigger consideration of premature ovarian insufficiency and other causes—not an automatic “ordinary perimenopause” label.
Between 40 and 45, biochemical testing may be considered when the picture is unclear.
Over 45, a typical history often does not require hormone testing to diagnose or manage perimenopause.

So the clean version is this: age does not assign the STRAW+10 stage; age changes the differential diagnosis and the next clinical step.

Why does every website give a different number of stages?

Different sources count differently because they are not using the same definition. STRAW+10 has two clinical transition stages. WHO defines a broader perimenopause window that ends one year after the final period. The 2025 ESE guideline is about clinical recognition, while CeMCOR offers a separate, explicitly non-consensus “very early” framework.

We compared the source definitions directly rather than counting whatever labels happened to appear in a consumer article.

Source or framework	What it is trying to do	When perimenopause or the transition starts	When it ends	Can regular-cycle symptoms fit?	What it can reliably give you
STRAW+10	Standardize reproductive-aging stages for research and clinical communication	Early transition begins at a persistent 7-day-or-greater difference between consecutive cycle lengths	The menopausal transition ends at the final menstrual period; postmenopause begins after it	Symptoms can occur, but regular cycles do not meet the Stage −2 bleeding criterion	A reproducible stage based mainly on observable bleeding patterns
World Health Organization	Define menopause and the broader perimenopause period for public health	When signs of the transition are first observed	One year after the final menstrual period	Potentially, because the definition is broader than the STRAW bleeding threshold	A broad time window, not a numbered personal stage
The Menopause Society patient guidance	Explain practical cycle and symptom changes	Subtle period changes may appear first; cycle variation can reach 7 days or more	Menopause is confirmed after one year without a period	Yes, subtle changes may precede the formal threshold	Practical tracking and care guidance, not a diagnostic calculator
European Society of Endocrinology 2025 guideline	Guide clinical recognition and management	Perimenopause should be considered with menstrual irregularity and/or vasomotor symptoms, including ages 40–45	It treats menopause as a spectrum including peri- and postmenopause	Yes—vasomotor symptoms alone can justify considering it clinically	A reason to investigate and discuss care; not a numbered STRAW stage
CeMCOR / Dr. Jerilynn Prior	Describe an earlier symptom-led phase	Regular 21–35-day cycles plus any 3 of 9 listed changes	Its own multistage timeline	Yes	A structured conversation checklist; CeMCOR explicitly states that it differs from the official consensus

No wonder you're confused. These sources are not all wrong. They are measuring different things.

So here's the honest reconciliation, and you can hold onto this one:

There are two official menopausal-transition stages. This page uses four practical checkpoints because the real-life question often begins before the calendar threshold and does not end until menopause is confirmed.

This matters more than it sounds. If a page tells you there are four official stages and then sells you a test to reveal your exact one, it has quietly swapped a useful teaching frame for a product claim.

Which stage of perimenopause am I in?

Your cycle history is the strongest practical staging clue when natural bleeding is still observable. A persistent 7-day-or-greater difference between consecutive cycle lengths supports early-transition staging. One interval of 60 days or more supports late-transition staging. Symptoms and a single hormone result cannot assign either stage on their own.

You need three things: a calendar, the first day of your last several periods, and about two minutes.

How to count a cycle—because this is where people get tripped up

Day 1 is the first day of menstrual flow. Do not count the day before. If spotting usually precedes your period, record it separately.
Cycle length runs from Day 1 of one period to Day 1 of the next.
Do not compare yourself with a textbook 28-day cycle. Compare your consecutive cycles with each other.

The 7-day rule, worked

Say your cycle lengths are:

Cycle 1: 28 days
Cycle 2: 20 days
Difference: 8 days

That crosses the early-transition threshold. But one odd cycle is not enough. STRAW+10 operationalizes “persistent” as the variable-length pattern recurring within 10 cycles of the first qualifying difference.

That word persistent is doing a lot of quiet work, and most explanations skip it.

One stressful month, one illness, one medication change, or one unusually timed period does not automatically stage you. A recurring pattern within 10 cycles is the stronger signal.

The 60-day rule, worked

Count from the start of one period to the start of the next. If the interval reaches 60 days, the pattern meets the late-transition bleeding marker when the bleeding is natural and another cause does not explain the gap.

Two details worth knowing:

In about one-third of women in the reviewed cohorts, the first cycle of 60 days or more was actually at least 90 days.
In women younger than 45, a clinician may look for a repeated 60-day interval or investigate other causes before treating one long gap as late transition.

It does not always creep. Sometimes it jumps.

If you never tracked anything

That's most people. Do this:

Reconstruct only what you can verify from calendar entries, messages, travel, purchases, photos, or a period app.
Start recording Day 1 now.
Record how many days you bleed and whether the flow changed.
Note bleeding between periods, after sex, or after a long gap.
Do not invent dates you cannot remember. A confident wrong calendar is worse than an honest incomplete one.

Three cycles can start a useful conversation. Six or more make the pattern easier to see. Ten cycles let you apply the persistence window more completely.

Copyable cycle-pattern worksheet

Period start date	Cycle length from the previous start	Difference from the previous cycle length
1.	—	—
2.		—
3.
4.
5.
6.
7.
8.
9.
10.

Calculation: subtract the shorter consecutive cycle length from the longer one. A result of 7 or more days is a qualifying difference. Then look forward across the next 10 cycles for recurrence.

The calendar can show whether your recorded pattern resembles a clinical stage. It cannot tell you which provider model fits your symptoms, uterus status, risk history, medication preference, insurance, budget, and state.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

→ Find your safest HRT starting point (about 90 seconds, no email required; a licensed clinician makes all treatment decisions)

Can you be in perimenopause with regular periods?

Yes, symptoms or subtle changes can begin while your periods still look regular—but a regular calendar does not automatically establish a clinical transition stage. STRAW+10 requires a persistent cycle-length change, the 2025 ESE guideline says vasomotor symptoms can justify considering perimenopause, and CeMCOR uses a separate non-consensus symptom checklist.

This is the section you came for. Let's take it apart.

First, the number that should end the argument

Twelve percent to 25% of women in the cohorts reviewed by STRAW+10 lead author Siobán Harlow experienced minimal or no change in cycle length before the final menstrual period.

Read that again. Somewhere between roughly one in eight and one in four women did not show the classic, obvious cycle-length progression before menopause.

If you have symptoms and regular-looking periods, you are not an anomaly. But the statistic does not diagnose you. It shows why one calendar criterion cannot settle every woman's experience.

Three frameworks, three different jobs

	STRAW+10	ESE clinical guideline, 2025	CeMCOR / Dr. Jerilynn Prior
What it is	Research and clinical staging standard	Clinical practice guideline, endorsed by the Endocrine Society	University research center's explicitly non-consensus framework
Can regular cycles fit?	Regular cycles do not meet the early-transition bleeding criterion	Perimenopause should be considered when menstrual irregularity and/or vasomotor symptoms are present	Yes; it calls regular cycles plus a symptom pattern “Very Early Perimenopause”
What a normal FSH means	FSH is supporting, not the primary stage marker	A normal FSH in a fertile-age woman does not rule out perimenopause	CeMCOR advises against using FSH as a stand-alone diagnosis
What it gives you	A reproducible stage when natural cycle data are usable	Permission to evaluate and discuss perimenopause before a textbook calendar change	A concrete symptom checklist to bring into a conversation
What it cannot do	Explain every symptomatic regular-cycle case	Turn symptoms alone into an exact numbered stage	Claim consensus status or prove that perimenopause is the cause

You may not have been dismissed because you were wrong. You may have walked into a system using a staging framework for a question it was never built to answer.

The nine changes CeMCOR uses

For women in midlife whose cycles remain 21 to 35 days apart, CeMCOR says any three of the following support what it calls “Very Early Perimenopause”:

New heavy and/or longer menstrual flow
Shorter cycles—25 days or fewer
New sore, swollen, or lumpy breasts
New or increased menstrual cramps
New mid-sleep waking
Night sweats beginning, especially around a period
New or much worse migraines
New or increased premenstrual mood swings
Noticeable weight gain without a change in food or exercise

Be clear-eyed about what this is. It is not a consensus diagnostic standard, and CeMCOR says so itself. It is a clinician-researcher's structured checklist. Its value is that it can turn “I feel off” into three specific, written-down changes you can put in front of a clinician.

CeMCOR estimates that its “very early” phase may last two to five years. Treat that as part of CeMCOR's framework—not as an official STRAW+10 duration.

It isn't just you—there is now a number for the uncertainty

A large mixed-methods study published online in July 2026 surveyed 7,640 US women aged 35 and older. It found:

34% were unsure of their reproductive stage.
Uncertainty peaked at 42% among women aged 40 to 44.
37% of women with severe symptom burden were still unsure.
Among the 409 women who explained their uncertainty in free text, 56% described symptom confusion and difficulty attributing bodily changes.

The study's point was not that every uncertain woman had perimenopause. It was that menstrual irregularity alone leaves a large group without a usable explanation, and clinical recognition needs to include symptom patterns and other possible causes.

One honest limit: participants were recruited through a health app, 63% identified as White, and the sample was not a nationally representative census. It is a large sample finding, not a national prevalence estimate.

It isn't in your head. It's in a definitional gap.

Does this sound like your situation? Write down the three changes that are most new, most disruptive, and most repeatable. Then use Find My HRT Path to see which care route fits—and whether an in-person evaluation should come first.

How long does each stage of perimenopause last?

There is no fixed duration and no personal countdown clock. After age 40, the median time from the first persistent 7-day cycle difference to the final period was about 5 to 8 years in reviewed cohorts. From the first 60-day interval, the median was about 2.5 to 3 years.

Real numbers, from real cohorts—but population medians are not appointments on your calendar.

Marker you have reached	Population timing reported in reviewed cohorts	What you can safely take from it
First persistent 7-day-or-greater cycle difference after age 40	Median 5 to 8 years to the final menstrual period	Early transition can be a long runway
First 60-day-or-longer interval after age 40	Median about 2.5 to 3 years to the final menstrual period	Late transition is generally closer, but still not predictable for one woman
Entire menopausal transition when it is not sudden	Approximately 4 to 10 years	There is no universal “four-year perimenopause”
Transition duration by age at onset in SWAN	Approximately 4.4 to 8.6 years, with longer duration when transition began younger	Earlier onset was associated with a longer transition

The number that changes how “wait and see” feels

The Study of Women's Health Across the Nation followed 3,302 women across seven US sites. Among 1,449 women who reported frequent hot flashes or night sweats, the median total duration of those symptoms was 7.4 years. Among the 881 women whose final menstrual period was observed, symptoms continued for a median 4.5 years afterward.

When the researchers split women by the stage at which frequent symptoms began:

Women who were premenopausal or in early perimenopause at onset had a median total duration of more than 11.8 years, with a median 9.4 years after the final period.
Women whose frequent symptoms began after menopause had the shortest median total duration, 3.4 years.

So if frequent hot flashes started while your cycles were still regular or only beginning to wobble, “just wait it out” is not neutral advice. In that cohort, the median for women whose symptoms began early was more than a decade.

That does not mean your symptoms will last 11.8 years. Stage at onset was associated with duration across a population; it was not a personal forecast and does not prove what any treatment will do to the total timeline.

Now the honest limitation

Here is what this page cannot do, and what no page can.

It cannot tell you the date of your final period. No blood test, app, symptom checklist, cycle algorithm, or framework—including this one—can hand you an honest personal menopause date.

We'd rather say that plainly than pretend.

But look at what staging actually buys you instead. It lets you say, “My cycles changed from 29 days to 20 days twice within eight cycles,” instead of “I feel off.” It gives you a population runway rather than a fake deadline. And it tells you that frequent vasomotor symptoms beginning early can last much longer than the old “a year or two” story suggests.

A date would be nice. A criterion, a realistic range, and a cleaner clinical conversation are the things that can change what you do next.

If what you need is a fertility answer

That is a different question. AMH and antral follicle count can help assess ovarian reserve and predict ovarian response in fertility treatment, but they are poor stand-alone predictors of natural conception and do not tell you exactly how many fertile years remain or when your final period will occur.

If pregnancy is on your list, say so directly to a clinician or reproductive specialist. Do not let a symptom-staging page—or a commercial “fertility clock”—make that decision for you.

Progress is not a straight line

CeMCOR cites a study of 324 menstruating women over 45 who were followed every six months for three years. Researchers identified 100 different menstrual patterns, including women who had six months without bleeding and then returned to six months of regular cycles.

If your body seems to be doing this “wrong”—skipping, returning, changing direction—you are not failing the process. The process is variable.

What symptoms show up at each stage of perimenopause?

Symptoms overlap heavily and cannot assign a stage. Hot flashes and night sweats often become more common in the late transition and can continue after the final period. Vaginal, vulvar, sexual, and urinary symptoms may appear later and often persist or worsen without treatment. The calendar carries more staging weight than symptom intensity.

Here is the honest map.

Symptom or pattern	Can begin before obvious cycle change?	Can happen in early transition?	Can happen in late transition?	Can continue after menopause?	Does it assign a stage?
Hot flashes and night sweats	Yes	Yes	Yes, commonly	Yes, sometimes for years	No
Broken sleep or mid-sleep waking	Yes	Yes	Yes	Yes	No
Mood changes, irritability, or anxiety	Yes	Yes	Yes	Sometimes	No
Concentration or word-finding problems	Yes	Yes	Yes	Sometimes	No
Breast soreness or fullness	Yes	Yes	Sometimes	Less typical	No
Heavier or longer bleeding	Yes	Yes	Yes	Not after natural menopause	No—evaluate the pattern
Vaginal dryness, painful sex, or urinary symptoms	Sometimes	Yes	Yes	Yes	No
Shorter cycles	Yes	Common in early transition	Can still occur	—	Suggestive, not enough alone
Very long cycles	Less typical	Can occur	Commoner in late transition	—	Suggestive
One 60-day interval without bleeding	—	Not the early-stage marker	Yes	—	Supports late-transition staging when calendar data are applicable

Heavy and prolonged bleeding is common—and still deserves attention

In SWAN, about three-quarters of women experienced three or more bleeding episodes lasting 10 days or longer during the transition, and about one-third had three or more heavy-bleeding episodes lasting at least 3 days.

Common does not mean “ignore it.” It means you are not imagining it—and the amount, duration, timing, and effect on iron levels still matter. Our irregular periods guide goes deeper.

Hot flashes are not a countdown clock

Harlow's review found that hot flashes, though common in late transition, did not predict proximity to the final period without information about amenorrhea and FSH.

If you are using the intensity of your hot flashes to estimate how close menopause is, stop. It does not work that way.

Vaginal and urinary symptoms behave differently

Vasomotor symptoms often improve with time. Genitourinary syndrome of menopause can persist or worsen with prolonged estrogen deficiency, and treatment may need to continue long term.

If vaginal dryness, painful sex, recurrent urinary symptoms, or irritation is your main issue, go to Vaginal Estrogen. That is a different conversation with a different answer.

For the full symptom inventory, use the Perimenopause Symptoms Checklist. Symptoms tell you what needs attention. Stages tell you what your calendar pattern supports.

Can a blood test tell you what stage of perimenopause you're in?

Usually not by itself. FSH and estradiol fluctuate across the transition, so a single result is a snapshot of a moving target. A normal FSH does not rule out perimenopause, and one elevated result does not reveal an exact stage or countdown. Testing is most useful when it answers a specific clinical question.

This is the section that costs some websites money, which is exactly why we are writing it.

Why FSH can mislead

FSH—follicle-stimulating hormone—is part of the signal from the brain to the ovaries. It often rises as reproductive aging progresses. It does not rise in a smooth, one-way line.

FSH can fluctuate for years.
A normal FSH does not rule out perimenopause. The 2025 ESE guideline states that directly.
An FSH level above 25 IU/L can support a late-transition or perimenopause assessment when the timing and clinical context fit, but it is not a standalone stage test.
In SWAN and the Melbourne cohort, a 60-day interval without bleeding predicted proximity to the final period better than a single early-follicular FSH result.
Hormonal contraception can alter bleeding and may make calendar or laboratory interpretation method-specific. Do not stop contraception just to “test” a stage without a care plan.

Your calendar can outperform one blood draw. For free.

Why estradiol can mislead too

Estradiol can be high, low, or highly variable during perimenopause. The value depends on timing, ovarian activity, medication, and the question being asked. One result does not reliably distinguish “early” from “late” for an individual woman.

Even the current FDA prescribing information for EstroGel states that serum FSH and estradiol levels have not been shown useful for managing moderate to severe vasomotor symptoms or vulvar and vaginal atrophy in postmenopausal women.

That label statement is about treatment management—not a universal ban on labs. The point is narrower and more useful: symptom care should not be reduced to chasing one hormone number.

What about saliva, dried urine, and “advanced hormone panels”?

Be careful here.

The Menopause Society states that salivary and urine hormone testing used to determine dosing is unreliable and not recommended; serum testing is rarely needed for routine hormone-therapy dosing.

We'll say the uncomfortable part out loud: a test can produce an impressive report without producing a valid stage. If a page answers “Which stage am I in?” by selling a urine or saliva panel, ask whether the test has been validated to assign STRAW+10 stages—and whether the seller benefits from the answer.

When testing genuinely helps

Testing is useful when it has a job. A clinician may use tests to investigate:

Symptoms or cycle disruption before age 40, when premature ovarian insufficiency needs consideration
An unclear picture between 40 and 45
Pregnancy
Thyroid disease
Anemia or iron deficiency after heavy bleeding
Hyperprolactinemia, hypothalamic amenorrhea, PCOS, or another endocrine cause
Bleeding that cannot be interpreted because of surgery, contraception, medication, chronic illness, or treatment

The 2025 ESE guideline says biochemical testing is generally unnecessary for diagnosis or management in women over 45 with a typical presentation, can be considered at ages 40 to 45, and is recommended in the evaluation of possible POI under 40.

Tests answer clinical questions. They do not hand out stage labels.

What actually changes at each stage of perimenopause?

The practical changes are narrower than most people expect: how much your calendar can tell you, whether contraception is still needed, how bleeding is interpreted, and what other causes should be ruled out. Your stage does not choose a treatment. Symptom burden, uterus status, pregnancy goals, medical history, route preference, and risk do.

Contraception: this one is not optional when pregnancy is not wanted

You can still become pregnant during perimenopause. Ovulatory cycles become less frequent, but they continue through the end of reproductive life.

In a SWAN daily-hormone study, 22.8% of observed cycles within one year of the final menstrual period were ovulatory. That is a cycle-level research finding, not an individual pregnancy probability. Its practical meaning is simple: ovulation does not shut off cleanly before the final period.

The Menopause Society advises continuing contraception until menopause is confirmed one year after the final menstrual period. CDC guidance says ACOG and The Menopause Society recommend continuing contraception until menopause or approximately age 50 to 55, and notes that no reliable lab test confirms definitive loss of fertility.

And one thing that trips people up constantly: menopausal hormone therapy is not contraception. If you need both symptom treatment and pregnancy prevention, those are two separate jobs.

The treatment conversation changes—but it does not split into stage-based recipes

You do not need a perfect stage label before getting help. That is the myth this page exists to break.

Stage can shape the conversation:

Is contraception or cycle control still needed?
Is bleeding expected, medication-related, or unexplained?
Does a uterus require endometrial protection if systemic estrogen is prescribed?
Is the main problem vasomotor, sleep, mood, vaginal, urinary, bleeding-related, or something else?
Does the situation need an exam, imaging, or in-person workup before telehealth treatment?

It should not produce a formula like “early stage equals one hormone; late stage equals another.” The specifics belong with a licensed clinician. Types of HRT and HRT Benefits and Risks go deeper.

Before you shop: keep FDA-approved and compounded separate

This matters at every stage.

FDA-approved medications undergo FDA review for safety, effectiveness, and quality before marketing. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are dispensed.

Compounded is not a generic version of an FDA-approved drug. It is not “the same as” an FDA-approved product, and it should not be described as clinically proven to produce the same result. In its current telehealth-compounding guidance, FDA lists those as false or misleading promotional claims.

Compounding can serve a legitimate patient-specific need when an FDA-approved product cannot meet it—for example, a required dosage form or an allergy to an ingredient—but it is a separate category with separate evidence and oversight.

To check a product:

Search Drugs@FDA or the Orange Book using the product name, strength, dosage form, and manufacturer.
Do not treat an NDC number as proof of approval. FDA states that assignment of an NDC does not denote FDA approval.
Ask the provider whether the exact prescription is FDA-approved or compounded before you pay.

One more line that matters for women considering testosterone: testosterone is a Schedule III controlled substance in the United States and requires a prescription. Nothing about online care removes that controlled-substance status.

You now know more about your position than most women get told in a ten-minute appointment. The useful next step is matching your symptoms, risk history, uterus status, medication preference, insurance, and state to the right care route—not forcing a stage to choose a drug. → Get your best-fit HRT path (about 90 seconds, no email required, and it flags when online care should not be your first stop)

What if your periods can't tell you anything?

Calendar staging may be unreliable or impossible after hysterectomy, endometrial ablation, with PCOS, or when contraception, medication, illness, chemotherapy, or major weight change alters bleeding. In those situations, the honest result is not “nothing is happening.” It is “the standard calendar criteria cannot assign a reliable stage.”

If you're in this group, you have probably been quietly abandoned by most pages on this topic. Let's fix that.

STRAW+10 says its bleeding criteria are not directly applicable when the menstrual signal is unavailable or was already irregular for another reason. That limitation is built into the model. It is not a failure on your part.

Hysterectomy with ovaries retained

No periods does not mean your ovaries stopped functioning. The date of your hysterectomy is not automatically your menopause date when one or both ovaries were retained.

Without menstrual bleeding, a clinician may use:

Your age
Whether one or both ovaries remain
The timing and pattern of symptoms
Medication and treatment history
Other possible causes
Selective hormone testing when it would change the assessment

That can support a clinical judgment. It still may not produce a precise STRAW+10 stage.

Tracking cyclic symptoms can add context—especially symptoms that recur in a roughly monthly pattern—but the disappearance of that pattern is not a validated substitute for a final menstrual period.

Endometrial ablation

Ablation reduces or stops uterine bleeding by design. Your ovaries may keep cycling while the calendar signal becomes faint or disappears.

That means “12 months without bleeding” cannot automatically confirm menopause after ablation. The same symptom, age, medication, and selective-testing approach applies.

Hormonal IUD, pill, implant, or injection

Hormonal contraception can change, reduce, or stop bleeding, so the pattern may describe the method more than the menopausal transition.

The blood-test issue is method-specific. Some hormonal methods suppress FSH more than others, so the exact method, age, bleeding history, pregnancy needs, and reason for testing all matter.

Do not stop contraception just to “test” your stage without a plan. Ovulation can continue in perimenopause, and stopping may restore pregnancy risk before it clarifies anything.

PCOS

Long-standing infrequent or irregular cycles already break the bleeding assumptions behind the STRAW+10 thresholds. A 60-day interval may be usual for someone with PCOS rather than a new late-transition marker.

Record what changed from your own baseline. The clinical question becomes whether a new pattern, symptom cluster, or age-related change needs evaluation—not whether a generic calculator can force your history into a stage.

Chemotherapy, chronic illness, major weight change, or medication

Amenorrhea caused by cancer treatment, illness, nutritional compromise, medication, or major weight change can look identical to a late-transition interval on a calendar. The cause and reversibility are different.

A stage label should never replace the work of identifying why the bleeding stopped.

What we'd tell you if you're in any of these groups: your calendar may not be readable with the standard criteria. That does not make your symptoms less real. It means an honest tool should refuse to manufacture a stage—and help you build the history a clinician actually needs.

How do you know when perimenopause is over?

Natural menopause is confirmed after 12 consecutive months without menstruation when pregnancy, surgery, medication, or another cause does not explain the absence. The final menstrual period is therefore identified only in hindsight. Bleeding before the year is complete may restart the count; bleeding after the year needs prompt medical evaluation.

The mechanics are simple when natural periods remain observable: note the first day of the most recent period and count 12 clear months.

The interpretation is not always simple.

Bleeding before the 12 months are complete

A natural menstrual bleed at month eight means the earlier period was not yet confirmable as the final menstrual period. The observation clock starts again from that bleed.

That does not mean every pre-12-month bleed should be shrugged off. Heavy bleeding, prolonged bleeding, bleeding between periods, bleeding after sex, severe pain, pregnancy possibility, or a pattern that is new for you can still need evaluation.

Bleeding after 12 clear months

This is postmenopausal bleeding. Benign causes are possible, but it should not be reassured away before assessment.

ACOG changed its guidance in April 2026. For most patients presenting with postmenopausal bleeding, the initial evaluation should now include both transvaginal ultrasonography and endometrial tissue sampling. Ultrasound-only triage is reserved for selected patients with a single episode, a fully visualized endometrium measuring 4 mm or less, no strong endometrial-cancer risk factors, and reliable access to prompt follow-up.

That does not mean everyone receives the same sequence in every clinical setting. It means a thin ultrasound measurement is no longer treated as a universal free pass.

Bleeding that needs a look regardless of stage

Pattern	What to do
Soaking through a pad or tampon every hour for two to three hours, especially with weakness, dizziness, or feeling faint	Seek urgent medical care
Heavy bleeding with severe pain, shortness of breath, chest pain, or possible pregnancy	Seek urgent medical care
Bleeding lasting more than seven days	Arrange an evaluation
Bleeding between periods	Arrange an evaluation
Bleeding after sex	Arrange an evaluation
Cycles repeatedly less than 21 days apart	Arrange an evaluation
Any bleeding after 12 clear months without a natural period	Arrange prompt evaluation

MedlinePlus and Mayo Clinic include very heavy bleeding, prolonged bleeding, bleeding between periods, short cycles, postmenopausal bleeding, severe pain, weakness, and lightheadedness among reasons to contact a clinician or seek urgent care.

This table is not an exhaustive emergency list. If something feels acutely wrong, get help rather than waiting for a stage label.

After the 12 months

You are postmenopausal by the standard retrospective definition. That does not mean every symptom ends on that date.

Hot flashes may continue for years. Vaginal and urinary symptoms often persist or worsen without treatment. Early postmenopause is a real biological phase, not a switch from “symptomatic” to “finished.”

Menopause is a point in time you can only identify in hindsight. Postmenopause is the life stage after it. Neither means you missed your chance to ask for help.

When is it not perimenopause?

Pregnancy, thyroid disease, anemia, hyperprolactinemia, PCOS, hypothalamic amenorrhea, medication effects, fibroids, polyps, and other conditions can overlap with perimenopause. Under age 40, premature ovarian insufficiency needs a separate workup. Age, bleeding pattern, medical history, and the specific symptom—not one hormone number—determine what should be ruled out.

We'd be doing you a disservice if we let you leave with a stage label and nothing else.

Under 40

Do not let new menstrual irregularity, subfertility, or vasomotor symptoms get reduced to “early perimenopause, come back later.” The 2025 ESE guideline recommends considering and testing for premature ovarian insufficiency in women under 40 with that presentation.

POI is a separate diagnosis. It has its own confirmation process, cause evaluation, health implications, and treatment discussion.

Between 40 and 45

Perimenopause is possible. Early menopause is also clinically important. The ESE guideline says biochemical testing can be considered in this age group when symptoms or cycle changes make the diagnosis uncertain.

The point is not to demand a panel from everyone. It is to avoid treating age 42 exactly like age 52 when another diagnosis would change care.

At any age, ask what else fits

Depending on the symptom pattern, a clinician may consider:

Pregnancy
Thyroid disease
Iron deficiency or anemia, especially after heavy or prolonged bleeding
Hyperprolactinemia
PCOS
Functional hypothalamic amenorrhea related to energy deficit, stress, or intensive exercise
Medication effects, including anticoagulants and treatments that alter ovarian or uterine function
Fibroids, polyps, adenomyosis, or another structural cause of bleeding
Sleep, mood, migraine, metabolic, or other conditions that overlap with common perimenopause symptoms

Some situations belong with an in-person clinician first

Start in person—or use telehealth only as a bridge to in-person assessment—when there is:

Red-flag bleeding
New severe pelvic pain or a pelvic mass
Possible pregnancy complication
Symptoms or menstrual disruption before age 40
Unexplained amenorrhea
A complex cancer or clotting history
A need for examination, imaging, endometrial sampling, or another procedure
A calendar that cannot be interpreted after surgery, treatment, or long-standing irregular cycles

We'd rather send you to the right door than keep you on our page.

What if your clinician won't engage with this?

Bring dates, calculated cycle differences, bleeding changes, and the symptoms that affect daily life—not a self-diagnosis. If the conversation still stalls, a menopause-focused telehealth service may help with history, labs, and treatment planning, but red-flag bleeding, procedures, and some complex histories still belong with in-person care first.

The training gap is real, but it should be described proportionally. In a 2022 survey completed by 99 U.S. obstetrics and gynecology residency program directors, only 31.3% reported having a menopause curriculum. That is a survey of programs—not proof that a particular clinician is unqualified.

Before changing clinicians, make the information hard to dismiss:

Bring the first day of each recent period.
Show the calculated cycle lengths and differences.
Circle any interval of 60 days or more.
List bleeding outside your usual pattern.
Name the three symptoms that disrupt your life most.
State your pregnancy intentions and current contraception.
Ask directly: “What else should we rule out, and what can we treat now?”

If you still need a different route, these are the two services on this page. The HRT Index may earn a commission if you use a sponsored link. That does not change your price. See our affiliate disclosure.

Provider-stated vs documentation-verified care routes

Verified August 3, 2026. This is a documentation audit of current provider pages and terms—not a claim that The HRT Index completed a visit or received treatment.

Route	Provider-stated offer	What The HRT Index verified in primary provider documents	Best fit on this page	Do not choose it for
Midi Health	Menopause-focused virtual care, insurance billing, self-pay visits, lab ordering, hormonal and nonhormonal care	Available in all 50 states; insurance participation varies by plan and state; in-network with most PPO plans; $250 initial / $150 continued-care self-pay; generally uses Labcorp but can order elsewhere; no mandatory subscription; Medicare beneficiaries may use self-pay but cannot submit related claims; Medicaid and Medi-Cal patients cannot be treated even as self-pay	A menopause-focused evaluation when you want a clinician who can order labs and coordinate an ongoing care plan	Medicaid or Medi-Cal; urgent bleeding; a procedure or examination that cannot be done virtually
Sesame menopause subscription	Dedicated provider, video care, messaging, prescriptions, and basic labs if needed	$59 per month on the current menopause page; medication cost is separate and varies by pharmacy/insurance; Sesame does not bill insurance; current terms require subscription cancellation at least 48 hours before renewal and do not provide a prorated refund for the current term; Sesame prescription services do not include controlled substances	Cash-pay ongoing menopause care when the listed provider is licensed in your state and you want upfront subscription pricing	Medicare, Medicaid, or TRICARE beneficiaries under Sesame's current eligibility terms; testosterone prescribing; urgent bleeding; a needed in-person procedure
In-person gynecology, primary care, or community health center	Examination, imaging, tissue sampling, pregnancy evaluation, and local referrals	The exact price and coverage depend on the practice and plan; no affiliate claim is made here	Red-flag bleeding, pelvic pain, possible pregnancy, postmenopausal bleeding, unexplained amenorrhea, Medicaid, or a situation requiring examination or a procedure	A reader seeking only a convenient routine virtual discussion when no in-person workup is needed

Midi Health: where it fits—and where it doesn't

The limits first: Midi is not covered by Medicare, although Medicare beneficiaries can use self-pay and agree not to submit related claims. Midi cannot treat Medicaid or Medi-Cal beneficiaries, even as self-pay. Insurance coverage depends on the exact plan, state, deductible, coinsurance, and copay.

Where it fits: Midi offers menopause-focused virtual visits in all 50 states, orders labs when clinically needed, and does not require a recurring membership. Current published self-pay prices are $250 for the initial visit and $150 for continued-care visits.

Midi prescribes FDA-approved options and also markets separate compounded products in parts of its Custom Rx offering. A compounded prescription is not FDA-approved. Ask whether the exact medication proposed for you is FDA-approved or compounded before agreeing to it.

→ Check whether Midi is in network for your plan and see the current self-pay price (sponsored link; coverage and clinical eligibility are confirmed during intake)

Sesame: where it fits—and where it doesn't

The limits first: Sesame is cash-pay and does not bill third-party insurance. Its current Terms of Service require users to certify that they are not Medicare, Medicaid, or TRICARE beneficiaries. Medication costs are not included in the $59 monthly menopause subscription. Sesame's prescription services do not include controlled substances, so this is not a route for online testosterone prescribing.

Where it fits: the current menopause program includes a chosen provider, video visits, unlimited messaging, prescriptions when clinically appropriate, and basic lab work if necessary. Medication is sent to the reader's chosen pharmacy; actual medication cost depends on the drug, insurance, and pharmacy.

For cancellation, Sesame's current terms say to cancel at least 48 hours before renewal by the stated support channels. Access continues through the paid term, but the unused part of that term is not prorated.

→ See Sesame's current menopause price and providers available for your state (sponsored link; medication cost and clinical eligibility are separate)

If you're on Medicaid—or need an exam—neither sponsored route is the answer

We'd rather lose the click than send you into a dead end.

Use your plan directory, primary care clinician, gynecology practice, or a federally qualified health center. For postmenopausal bleeding, major bleeding, severe pain, possible pregnancy, or a needed biopsy or ultrasound, start with a route that can arrange the in-person workup.

What did The HRT Index actually verify for this page?

The HRT Index checked the staging criteria, timing data, regular-cycle conflict, testing limits, fertility guidance, bleeding warnings, 2026 postmenopausal-bleeding update, and every commercial fact in the provider table against primary or authoritative sources. Provider facts were document-verified; no visit, treatment, testimonial, or firsthand clinical result is claimed.

This page was built under The HRT Index Verification Standard—the documented process used to read published prices, separate FDA-approved from compounded options, verify availability and insurance, and re-check commercial facts on a fixed schedule.

The five pillars are always evaluated in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish numeric provider scores.

What we checked on August 3, 2026

STRAW+10's two transition stages, the 7-day criterion, the 60-day criterion, and the definition of persistence
The broader WHO perimenopause definition
The 12% to 25% minimal-cycle-change finding and population timing estimates
The 2025 ESE recommendations on regular-cycle symptoms, age, FSH, and testing
CeMCOR's nine-item checklist and its explicit non-consensus status
The 2026 reproductive-stage uncertainty study and its sampling limits
Vasomotor-symptom duration by stage at onset
The limits of FSH, estradiol, AMH, saliva, and urine testing
Fertility and contraception guidance
FDA language separating approved and compounded medications
Testosterone's Schedule III status
The April 2026 ACOG postmenopausal-bleeding update
Midi's current published prices, insurance rules, state reach, lab process, and subscription model
Sesame's current price, included care, separate medication cost, insurance position, controlled-substance limit, and cancellation terms
The current Find My HRT Path landing page: about 90 seconds, no email required, and a care-route match—not a cycle-stage calculator

What this verification does not claim

It does not diagnose your stage or the cause of a symptom.
It does not predict the date of your final menstrual period.
It does not mean The HRT Index signed up for or received care from Midi or Sesame.
It does not guarantee insurance payment, a prescription, a particular medication, or provider availability.
It does not replace examination, imaging, tissue sampling, or urgent care when those are needed.

Who made this and why: The HRT Index Editorial Team created this page to turn an inconsistent set of definitions into a usable decision map. It is editorial research, not medical advice, and it has not been reviewed by a clinician. See our medical review policy and corrections page. To report an error, email corrections@thehrtindex.com.

Frequently asked questions about the stages of perimenopause

These short answers cover the follow-ups most likely to leave a reader stuck: what “four stages” means, whether regular periods count, how pregnancy and testing fit, what changes after hysterectomy or an IUD, how long late transition lasts, and when bleeding needs medical evaluation.

What are the 4 stages of perimenopause?

There are two official menopausal-transition stages in STRAW+10: early and late. A practical four-checkpoint map adds possible early changes before the threshold and the 12-month menopause-confirmation window after the final period. That four-part map is useful, but it should not be called four official clinical transition stages.

What is the first stage of perimenopause?

The first official transition stage is the early menopausal transition, STRAW+10 Stage −2. It begins when consecutive cycle lengths differ by 7 days or more and that variable pattern recurs within 10 cycles. Symptoms may begin earlier, but they do not assign this stage by themselves.

How do I know what stage of perimenopause I'm in?

Compare the start dates of natural periods. A persistent 7-day-or-greater difference between consecutive cycle lengths supports early-transition staging. One interval of at least 60 days supports late-transition staging. The result should be described as a pattern that resembles a stage—not a diagnosis of every symptom.

What stage am I in if I skipped one period?

Count the days between period start dates. An interval of at least 60 days meets the late-transition bleeding marker when the cycles are natural and another cause does not explain the gap. A shorter missed or late period does not meet that marker, and pregnancy, illness, medication, stress, or another cause may need consideration.

Can you be in perimenopause with regular periods?

Yes, symptoms or subtle changes can begin while cycles still look regular. That does not automatically meet the STRAW+10 early-transition criterion. The 2025 ESE guideline says perimenopause should still be considered when menstrual irregularity and/or vasomotor symptoms are present, while CeMCOR uses a separate non-consensus symptom checklist for an earlier phase.

Can perimenopause start in your 30s?

Menopause-related symptoms and cycle changes can occur before 40, but the correct next step is an evaluation for premature ovarian insufficiency and other causes—not an automatic ordinary-perimenopause label. POI has a separate diagnostic pathway and health implications, so delaying that workup matters.

Does perimenopause move through the stages in a straight line?

Not neatly. Cycles can shorten, lengthen, skip, and then look regular again. The stage criteria identify qualifying patterns across time; they do not promise a smooth one-way progression or an exact countdown to the final period.

What's the difference between perimenopause and the menopausal transition?

The menopausal transition is the two-stage STRAW+10 period before the final menstrual period. WHO uses a broader perimenopause definition that begins with transition signs and ends one year after the final menstrual period. The terms overlap, but their boundaries are not identical.

Can you still get pregnant in late perimenopause?

Yes. Ovulation becomes less frequent but can still occur before the final menstrual period. Continue contraception when pregnancy is not wanted until menopause has been confirmed under guidance appropriate to your age and contraceptive method. Menopausal hormone therapy is not contraception.

Do symptoms get worse in the later stages?

There is no guaranteed mild-to-severe ladder. Hot flashes and night sweats are common in late transition and early postmenopause, but they can begin earlier and persist for years. Vaginal and urinary symptoms often become more prominent later and may persist without treatment. Symptom intensity does not assign a stage.

Can an FSH test tell me my stage?

Usually not by itself. FSH fluctuates across the cycle and transition, and a normal value does not rule out perimenopause. Testing can help in selected situations—especially possible POI under 40 or an unclear picture at 40 to 45—but it should answer a defined clinical question rather than sell an exact stage.

How do I know my stage after a hysterectomy?

You generally cannot use the calendar criteria when there is no bleeding to observe. If one or both ovaries remain, the surgery date is not automatically the menopause date. Assessment uses age, ovarian status, symptoms, medical history, other causes, and sometimes selectively interpreted tests; a precise STRAW+10 stage may remain unavailable.

Can a hormonal IUD hide what stage I'm in?

Yes, because it can reduce or stop bleeding—the signal used by the calendar criteria. It does not create one universal hormone-test rule, however. Interpretation depends on the method, age, symptoms, and pregnancy needs. Do not remove or stop contraception solely to test a stage without discussing the plan with a clinician.

How long does late perimenopause last?

STRAW+10 describes late transition as roughly 1 to 3 years, and reviewed cohorts of women over 40 had a median of about 2.5 to 3 years from the first 60-day interval to the final period. Those are population estimates, not an individual deadline.

When should perimenopause bleeding be checked?

Seek urgent care for very heavy bleeding with weakness, dizziness, faintness, severe pain, or possible pregnancy. Arrange evaluation for bleeding lasting more than seven days, bleeding between periods or after sex, repeatedly short cycles, or any bleeding after 12 clear months without a natural period.

Where do you go from here?

You came here to find out where you are. Here's the honest summary: two clinical rules can stage an observable natural-cycle pattern—a persistent 7-day cycle-length difference and a 60-day interval without bleeding. Symptoms can start before either rule fires. A single blood test usually cannot settle it. And some women cannot be staged by a calendar at all.

What you do with that is the part that matters.

Track the dates you actually know. Calculate the differences. Bring three specific symptoms instead of one vague feeling. Name unusual bleeding. State whether pregnancy is possible or wanted. Ask what else should be ruled out—and what can be treated now.

The damaging admission still stands: no page, blood test, app, or clinician can hand you the date of your final period in advance.

But you do not need that date to stop drifting.

Still not sure which HRT program is right for you? Take our free matching quiz — about 90 seconds, no email required, and it tells you when online care isn't the right starting point.

Related reading:

Perimenopause Symptoms Checklist — symptoms tell you what needs attention; this page explains what the calendar can stage
Perimenopause Irregular Periods: Treatment Online — start here when bleeding is the main problem
Types of HRT — the treatment landscape after you understand the decision factors
HRT Benefits and Risks — the tradeoffs that belong in a treatment discussion
Vaginal Estrogen — for vaginal and urinary symptoms that often persist
Best Online HRT Providers — compare provider models after you know what kind of care you need

Last verified: August 2026. Educational research from The HRT Index Editorial Team. Not medical advice. Not reviewed by a clinician.

Sources

: Harlow SD, Gass M, Hall JE, et al. Executive Summary of the Stages of Reproductive Aging Workshop +10. Journal of Clinical Endocrinology & Metabolism. 2012;97(4):1159–1168. Primary consensus source for the STRAW+10 stage map.

: Harlow SD. Menstrual Cycle Changes as Women Approach the Final Menses: What Matters?. Obstetrics and Gynecology Clinics of North America. 2018;45(4):599–611. Primary review used for persistence, timing, 60-day intervals, limits, ovulation, and bleeding-pattern data.

: World Health Organization. Menopause. Current fact sheet accessed August 3, 2026.

: The Menopause Society. Perimenopause. Current patient guidance accessed August 3, 2026.

: Lumsden MA, Dekkers OM, Faubion SS, et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. European Journal of Endocrinology. 2025;193(4):G49–G81.

: Centre for Menstrual Cycle and Ovulation Research, University of British Columbia. How Can I Tell I Am in Perimenopause?. Current page accessed August 3, 2026; the page explicitly distinguishes its framework from consensus staging.

: Xu Y, Fergus D, Hewings-Martin Y, et al. Exploring prevalence and drivers of perimenopause uncertainty among US women: a mixed-methods study. Menopause. Published online July 14, 2026. DOI: 10.1097/GME.0000000000002837. The article reports the sample, recruitment method, and demographic limitations.

: Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531–539.

: American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. 2020.

: The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.

: DailyMed. EstroGel—estradiol gel prescribing information. Current label accessed August 3, 2026; section 5.19 states that serum FSH and estradiol levels have not been shown useful in managing moderate to severe vasomotor symptoms or vulvar and vaginal atrophy symptoms.

: U.S. Centers for Disease Control and Prevention. When Contraceptive Protection Is No Longer Needed. U.S. Selected Practice Recommendations for Contraceptive Use; current page accessed August 3, 2026.

: U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Current page accessed August 3, 2026.

: U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. Current FDA guidance accessed August 3, 2026.

: U.S. Food and Drug Administration. National Drug Code Directory. FDA states that inclusion in the directory or assignment of an NDC does not denote approval. Accessed August 3, 2026.

: U.S. Drug Enforcement Administration. Drug Scheduling. Testosterone is listed as a Schedule III controlled substance under U.S. federal law. Accessed August 3, 2026.

: MedlinePlus. Abnormal uterine bleeding; Mayo Clinic. Perimenopause—Symptoms and causes. Current patient-safety guidance accessed August 3, 2026.

: American College of Obstetricians and Gynecologists. Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstetrics & Gynecology. Published online April 16, 2026; July 2026 issue. DOI: 10.1097/AOG.0000000000006275.

: Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023;30(10):1003–1008.

: Midi Health. Pricing & Insurance. Prices and program eligibility verified August 3, 2026.

: Midi Health. Menopause care; How Midi Works; and Custom Rx. State reach, lab process, no-mandatory-subscription statement, and compounded-product disclosures checked August 3, 2026.

: Sesame. Online menopause treatment. Program price, included care, lab statement, and separate medication cost verified August 3, 2026.

: Sesame. Terms of Service. Insurance position, controlled-substance limit, cancellation window, renewal, and refund terms verified August 3, 2026.

: The HRT Index. Find My HRT Path. Live landing-page deliverable and timing checked August 3, 2026.

Keep reading: